Results 51 to 60 of about 6,510 (202)
Impact of extended-course oral nirmatrelvir/ritonavir in established Long COVID: a case series
Communications MedicineBackground Prior case series suggest that a 5-day course of oral Paxlovid (nirmatrelvir/ritonavir) benefits some people with Long COVID, within and/or outside of the context of an acute reinfection.
Alison K. Cohen +14 more
doaj +1 more source
Pharmacokinetics Profile and Genetics of Double Antiviral Therapy with Remdesivir and Nirmatrelvir/Ritonavir for Prolonged COVID-19 in Patients Treated with Rituximab: A Real-Life Study and Literature Review [PDF]
Introduction: Patients with hematologic malignancies are more likely to develop severe and prolonged SARS-CoV-2 infection, often showing viral persistence despite the use of authorized antivirals. Herein, we report the cases of four patients who received
Alice Palermiti +16 more
core +1 more source
American Journal of Industrial Medicine, Volume 69, Issue 5, Page 323-334, May 2026.ABSTRACT Hypersensitivity pneumonitis (HP) is an immune‐mediated interstitial lung disease triggered by repeated inhalation of organic or chemical antigens. Occupational exposures account for approximately 19% of all cases. Early diagnosis, identification of the responsible antigen(s), and immediate avoidance of exposure are crucial to prevent ...
Ludwig Frei‐Stuber +6 more
wiley +1 more source
PLoS ONE, 2023 BackgroundLarge observational studies have demonstrated the real-world effectiveness of nirmatrelvir-ritonavir in preventing severe COVID-19 in higher risk individuals, but have provided limited information on other aspects of nirmatrelvir-ritonavir use.
Valerie Leung +9 more
doaj +1 more source
Characteristics and outcomes of patients with COVID-19 at high risk of disease progression receiving sotrovimab, oral antivirals, or no treatment:a retrospective cohort study [PDF]
BACKGROUND: The clinical benefit of coronavirus disease 2019 (COVID-19) treatments against new circulating variants remains unclear. We sought to describe characteristics and clinical outcomes of highest risk patients with COVID-19 receiving early COVID ...
Birch, Helen J +8 more
core +3 more sources
Immunity, Inflammation and Disease, Volume 14, Issue 5, May 2026.ABSTRACT Objective To assess whether antivirals are associated with a reduced incidence of uveitis following COVID‐19. Methods We conducted a multi‐institutional, population‐based retrospective cohort study of adults (≥ 18 years) diagnosed with COVID‐19 between 2022 and 2024. Patients who received antiviral agents (Paxlovid, Molnupiravir, or Remdesivir)
Hou‐Ting Kuo +14 more
wiley +1 more source
Comparison between available early antiviral treatments in outpatients with SARS-CoV-2 infection: a real-life study [PDF]
, 2023 Purpose: To investigate the clinical impact of three available antivirals for early COVID-19 treatment in a large real-life cohort. Methods: Between January and October 2022 all outpatients tested positive for SARS-CoV-2 referring to IRCCS S.
Bonazzetti C. +16 more
core +1 more source
Carbohydrate‐Based Drug Discovery: Synthetic Strategies and Clinical Applications
Israel Journal of Chemistry, Volume 66, Issue 3, May 2026.The picture depicts the molecules discussed in the review. On the left side, the general scaffold of sugars is shown. Next to it are four carbohydrate‐based molecules, including remdesivir, islatravir, empagliflozin, and Globo‐H. Remdesivir and islatravir contain a substituted ribose ring attached to a modified nucleobase.
Stephan Scheeff +2 more
wiley +1 more source
Paxlovid in Kidney Failure: A Review [PDF]
The COVID-19 virus caused a global pandemic that claimed many lives. Various vaccines and drugs are used for COVID-19 both via intravenous and oral routes.
Ardianty, Nonie +2 more
core +2 more sources
BMC Infectious DiseasesBackground and aim Two oral antivirals (Nirmatrelvir- ritonavir and Azvudine) are widely used in China practice during the Omicron wave of the pandemic.
Xiaobo Han +20 more
doaj +1 more source